Holen Sie sich die Stockscreener-App
62.34
0.76%
-0.5387
Schlusskurs vom Vortag:
$62.88
Offen:
$62.47
24-Stunden-Volumen:
802.47K
Relative Volume:
0.37
Marktkapitalisierung:
$7.33B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
20.64
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
-6.21%
1M Leistung:
-8.55%
6M Leistung:
+14.76%
1J Leistung:
+27.20%
1-Tages-Spanne:
$61.71
$63.40
1-Wochen-Bereich:
$61.70
$67.10
52-Wochen-Spanne:
$46.26
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
62.34 | 7.39B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.32 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.26 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.61 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.75 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.55 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Marshall Wace LLP Has $20.24 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2Xideas AG Sells 62,256 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
James Lang elected to Halozyme Therapeutics board of directors - Investing.com
James Lang elected to Halozyme Therapeutics board of directors By Investing.com - Investing.com India
Halozyme Elects James Lang to Board of Directors - TipRanks
Halozyme Therapeutics Elects New Board Member - TradingView
Jim Lang elected to Halozyme’s board of directors By Investing.com - Investing.com India
Halozyme (NASDAQ: HALO) elects ex-EVERSANA CEO Jim Lang to board of directors - Stock Titan
Halozyme and Quinn Emanuel secure PI against MSD over Keytruda SC - JUVE Patent
Cash per share of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Halozyme wins German injunction blocking Merck’s Keytruda distribution - Indian Pharma Post
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Halozyme Therapeutics (HALO): Reassessing Valuation After Strong Year-To-Date Gains And Recent Momentum Slowdown - Yahoo Finance
Norges Bank Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. - Finviz
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Epoch Investment Partners Inc. Sells 195,366 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Kennedy Capital Management LLC Has $21.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group - MarketBeat
Citizens reiterates Market Outperform rating on Halozyme stock amid legal win - Investing.com
Why Halozyme Therapeutics Inc. stock could rally in 20252025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Merck suffers a setback over its new Keytruda formulation in Germany - statnews.com
Halozyme Therapeutics Inc RV7 Stock Analysis and ForecastPrice Action Analysis & The Smart Money Is Buying These Picks - earlytimes.in
Halozyme (HALO) Wins Injunction Against Merck in Germany - GuruFocus
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesTrade Risk Summary & Expert Curated Trade Setup Alerts - Newser
Halozyme (NASDAQ: HALO) gets German court order halting Keytruda SC over MDASE patent - Stock Titan
Halozyme Therapeutics downgraded by Goldman with a new price target - Quantisnow
Goldman Sachs downgrades Halozyme stock to Sell on looming revenue cliff - Investing.com Nigeria
Is Halozyme Therapeutics Inc. stock dividend yield sustainable2025 Support & Resistance & Capital Protection Trading Alerts - Newser
Mackenzie Financial Corp Has $6.16 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by CW Advisors LLC - MarketBeat
Fisher Asset Management LLC Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Do Halozyme’s (HALO) Upgrades and Deals Justify Insider Sales or Complicate Its Royalty-Driven Story? - Yahoo Finance
Is Halozyme Still Attractive After 2025 Rally and Recent 11% Pullback? - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
What Analysts Now Think Gives Halozyme Therapeutics The Edge Amid Evolving Risks and Rewards - Yahoo Finance
Skandinaviska Enskilda Banken AB publ Sells 16,900 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Granite Investment Partners LLC Lowers Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arrowstreet Capital Limited Partnership Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. (RV7) stock test record highs in 2025Weekly Loss Report & Verified Momentum Stock Ideas - Newser
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliableMarket Sentiment Report & Real-Time Buy Signal Notifications - Newser
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 Earnings & Reliable Entry Point Alerts - Newser
RENAISSANCE GROUP LLC's Halozyme Therapeutics Inc(HALO) Holding History - GuruFocus
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells 829 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 16,569 Shares - MarketBeat
After Recent Drug Partnership Deals, Is Halozyme Still a Hidden Gem in 2025? - Sahm
Halozyme Therapeutics (HALO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarInsider Buying & AI Enhanced Trading Signals - Newser
Quadrature Capital Ltd Buys 11,662 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Dec 01 '25 |
Option Exercise |
8.11 |
16,569 |
134,375 |
725,288 |
| Torley Helen | PRESIDENT AND CEO |
Dec 01 '25 |
Sale |
68.92 |
16,569 |
1,141,925 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Sale |
70.55 |
20,000 |
1,410,990 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Sale |
69.13 |
20,000 |
1,382,600 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Sale |
68.72 |
20,000 |
1,374,339 |
733,719 |
| Connaughton Bernadette | Director |
Nov 10 '25 |
Sale |
68.48 |
2,000 |
136,960 |
42,952 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
1.22%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):